KR850002277A - 동결건조 b형 간염 왁진조성물 및 그 제조방법 - Google Patents
동결건조 b형 간염 왁진조성물 및 그 제조방법 Download PDFInfo
- Publication number
- KR850002277A KR850002277A KR1019840003814A KR840003814A KR850002277A KR 850002277 A KR850002277 A KR 850002277A KR 1019840003814 A KR1019840003814 A KR 1019840003814A KR 840003814 A KR840003814 A KR 840003814A KR 850002277 A KR850002277 A KR 850002277A
- Authority
- KR
- South Korea
- Prior art keywords
- hepatitis
- wax composition
- lyophilized
- group
- gel
- Prior art date
Links
- 208000002672 hepatitis B Diseases 0.000 title claims 12
- 239000000203 mixture Substances 0.000 title claims 11
- 238000002360 preparation method Methods 0.000 title 1
- 239000000499 gel Substances 0.000 claims 6
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 claims 5
- 229910052782 aluminium Inorganic materials 0.000 claims 5
- 235000001014 amino acid Nutrition 0.000 claims 5
- 150000001413 amino acids Chemical class 0.000 claims 5
- 238000004108 freeze drying Methods 0.000 claims 5
- 150000003839 salts Chemical class 0.000 claims 5
- SRBFZHDQGSBBOR-IOVATXLUSA-N D-xylopyranose Chemical compound O[C@@H]1COC(O)[C@H](O)[C@H]1O SRBFZHDQGSBBOR-IOVATXLUSA-N 0.000 claims 4
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 claims 4
- 239000000427 antigen Substances 0.000 claims 4
- 102000036639 antigens Human genes 0.000 claims 4
- 108091007433 antigens Proteins 0.000 claims 4
- 150000001720 carbohydrates Chemical class 0.000 claims 4
- 239000003381 stabilizer Substances 0.000 claims 4
- -1 garactose Chemical compound 0.000 claims 3
- 238000000034 method Methods 0.000 claims 3
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 claims 2
- 239000004475 Arginine Substances 0.000 claims 2
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 claims 2
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 claims 2
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 claims 2
- 229930091371 Fructose Natural products 0.000 claims 2
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 claims 2
- 239000005715 Fructose Substances 0.000 claims 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims 2
- 239000004471 Glycine Substances 0.000 claims 2
- 241000700721 Hepatitis B virus Species 0.000 claims 2
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 claims 2
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 claims 2
- 229930195725 Mannitol Natural products 0.000 claims 2
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 claims 2
- 230000000840 anti-viral effect Effects 0.000 claims 2
- PYMYPHUHKUWMLA-UHFFFAOYSA-N arabinose Natural products OCC(O)C(O)C(O)C=O PYMYPHUHKUWMLA-UHFFFAOYSA-N 0.000 claims 2
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 claims 2
- 235000009697 arginine Nutrition 0.000 claims 2
- SRBFZHDQGSBBOR-UHFFFAOYSA-N beta-D-Pyranose-Lyxose Natural products OC1COC(O)C(O)C1O SRBFZHDQGSBBOR-UHFFFAOYSA-N 0.000 claims 2
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 claims 2
- 229960002737 fructose Drugs 0.000 claims 2
- 239000008103 glucose Substances 0.000 claims 2
- 239000008101 lactose Substances 0.000 claims 2
- 229960001375 lactose Drugs 0.000 claims 2
- 239000000594 mannitol Substances 0.000 claims 2
- 235000010355 mannitol Nutrition 0.000 claims 2
- 229960001855 mannitol Drugs 0.000 claims 2
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 claims 2
- LPUQAYUQRXPFSQ-DFWYDOINSA-M monosodium L-glutamate Chemical compound [Na+].[O-]C(=O)[C@@H](N)CCC(O)=O LPUQAYUQRXPFSQ-DFWYDOINSA-M 0.000 claims 2
- 235000013923 monosodium glutamate Nutrition 0.000 claims 2
- 239000004223 monosodium glutamate Substances 0.000 claims 2
- 239000000600 sorbitol Substances 0.000 claims 2
- 235000010356 sorbitol Nutrition 0.000 claims 2
- 229960002920 sorbitol Drugs 0.000 claims 2
- 239000000811 xylitol Substances 0.000 claims 2
- 235000010447 xylitol Nutrition 0.000 claims 2
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 claims 2
- 229960002675 xylitol Drugs 0.000 claims 2
- OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 claims 1
- 229920001353 Dextrin Polymers 0.000 claims 1
- 239000004375 Dextrin Substances 0.000 claims 1
- 108010010803 Gelatin Proteins 0.000 claims 1
- 102000008100 Human Serum Albumin Human genes 0.000 claims 1
- 108091006905 Human Serum Albumin Proteins 0.000 claims 1
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 claims 1
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 claims 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 claims 1
- 239000004472 Lysine Substances 0.000 claims 1
- GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 claims 1
- 241000220317 Rosa Species 0.000 claims 1
- 229930006000 Sucrose Natural products 0.000 claims 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 claims 1
- 235000004279 alanine Nutrition 0.000 claims 1
- ILRRQNADMUWWFW-UHFFFAOYSA-K aluminium phosphate Chemical compound O1[Al]2OP1(=O)O2 ILRRQNADMUWWFW-UHFFFAOYSA-K 0.000 claims 1
- 229940024546 aluminum hydroxide gel Drugs 0.000 claims 1
- SMYKVLBUSSNXMV-UHFFFAOYSA-K aluminum;trihydroxide;hydrate Chemical compound O.[OH-].[OH-].[OH-].[Al+3] SMYKVLBUSSNXMV-UHFFFAOYSA-K 0.000 claims 1
- 239000007864 aqueous solution Substances 0.000 claims 1
- GUBGYTABKSRVRQ-QUYVBRFLSA-N beta-maltose Chemical compound OC[C@H]1O[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@@H]1O GUBGYTABKSRVRQ-QUYVBRFLSA-N 0.000 claims 1
- 150000001875 compounds Chemical class 0.000 claims 1
- 235000019425 dextrin Nutrition 0.000 claims 1
- 235000013681 dietary sucrose Nutrition 0.000 claims 1
- 238000007710 freezing Methods 0.000 claims 1
- 230000008014 freezing Effects 0.000 claims 1
- 239000008273 gelatin Substances 0.000 claims 1
- 229920000159 gelatin Polymers 0.000 claims 1
- 235000019322 gelatine Nutrition 0.000 claims 1
- 235000011852 gelatine desserts Nutrition 0.000 claims 1
- 238000001879 gelation Methods 0.000 claims 1
- 235000018977 lysine Nutrition 0.000 claims 1
- 229960002160 maltose Drugs 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 239000000463 material Substances 0.000 claims 1
- 230000006641 stabilisation Effects 0.000 claims 1
- 238000011105 stabilization Methods 0.000 claims 1
- 239000000126 substance Substances 0.000 claims 1
- 229960004793 sucrose Drugs 0.000 claims 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/29—Hepatitis virus
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2730/00—Reverse transcribing DNA viruses
- C12N2730/00011—Details
- C12N2730/10011—Hepadnaviridae
- C12N2730/10111—Orthohepadnavirus, e.g. hepatitis B virus
- C12N2730/10122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Virology (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Biophysics (AREA)
- Mycology (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Communicable Diseases (AREA)
- Immunology (AREA)
- Microbiology (AREA)
- Genetics & Genomics (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicinal Preparation (AREA)
Abstract
내용 없음
Description
본 내용은 요부공개 건이므로 전문내용을 수록하지 않았음
Claims (9)
- 비활성 정제 B형 간염 반이러스 표면항원에 알미늄겔과 안정화제를 첨가하고 또 이 혼합물을 동결건조시켜 제조되는 동결건조 상태의 알미늄겔상에 흡착된 비활성 정제 B형 간염 바이거스 표면항원과 안정화제로 구성되는 동결건조 B형 간염 왁진 조성물.
- 제1항에 있어서, 알미늄겔을 알미늄하이드록사이드겔 및 알미늄포스페이트겔로 구성되는 군에서 선정하는 동결구조 B형 간염왁진 조성물.
- 제1항에 있어서, 안정화제를 아미노산 또는 이의 염 및 사카니이드로 구성되는 군에서 선정하는 동결건조 B형 간염 왁진 조성물.
- 제3항에 있어서, 1개 이상의 아미노산 또는 이의 염과 1개 이상의 사카라이드가 함유된 동결건조 B형 간염 왁진 조성물.
- 제3항에 있어서, 안정화제가 1개 이상의 아미노산 또는 이의 염, 1개 이상의 사카라이드와 1개 이상의 콜로이드성 물질의 결합물질인 동결건조 B형 간염 왁진 조성물.
- 제4항에 있어서, 아미노산과 이의 염이 글리신, 아라닌, 1나트륨 글타메이트, 아르기닌 및 리신으로구성되는 군으로부터 선정하고 또 사카라이드가 글루코즈, 키실로즈, 가락토즈, 푸럭토즈, 락토즈, 사카로즈, 만니톨, 솔비톨 및 키실리톨로 구성되는 군으로부터 선정되는 동결건조 B형 간염 왁진 조성물.
- 제5항에 있어서, 아미노산과 이의 염이 글리신, 아라닌, 1나트륨 글루타메이트, 아르기닌 및 티신으로 구성되는 군으로부터 선정되고; 사카라이드가 글루코즈, 키실로즈, 가락토즈, 푸럭토즈, 락토즈, 말토즈, 사카로즈, 만니톨, 솔비톨 및 키실리톨로 구성되는 군으로부터 선정되며; 도 콜로이드성 물질이 제라틴, 인간알부민 및 덱스트린 중에서 선정되는 동결건조 B형 간염 왁진 조성물.
- 비활성 정제 B형 간염 바이러스 표면항원 수용액에 알미늄겔 및 안정화를 첨가하고: B형 간염 바이러스 표면항원이 알미늄겔 상에 흡착되어 있는 혼합물을 최소사용단위로 배분하며 또 각개 사용단위 혼합물을 동결시키는 동결건조 B형 간염 왁진의 제조방법.
- 제8항에 있어서, 동결건조 단계가 대기압하 저온에서 수시간 동안 행하는 예비 동결건조; 감압하의 보다 고온에서 10 나지 수십시간 동안 행하는 1차 동결건조; 와 보다 감압하의 승온상태에서 수신간 내지 10시간동안 행하는 3차 동결건조 단계의 3단계로 구성되는 동결건조 B형 간염 왁진의 제조방법.※ 참고사항 : 최초출원 내용에 의하여 공개하는 것임.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP58122945A JPS6013718A (ja) | 1983-07-05 | 1983-07-05 | Ｂ型肝炎ワクチン |
| JP83-122945 | 1983-07-05 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| KR850002277A true KR850002277A (ko) | 1985-05-10 |
| KR910005888B1 KR910005888B1 (ko) | 1991-08-06 |
Family
ID=14848502
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1019840003814A KR910005888B1 (ko) | 1983-07-05 | 1984-07-02 | 동결건조 b형 간염 왁진의 제조방법 |
Country Status (7)
| Country | Link |
|---|---|
| EP (1) | EP0130619B1 (ko) |
| JP (1) | JPS6013718A (ko) |
| KR (1) | KR910005888B1 (ko) |
| AT (1) | ATE41309T1 (ko) |
| AU (1) | AU572162B2 (ko) |
| CA (1) | CA1237076A (ko) |
| DE (1) | DE3477139D1 (ko) |
Families Citing this family (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS60193925A (ja) * | 1984-03-13 | 1985-10-02 | Chemo Sero Therapeut Res Inst | 凍結乾燥製剤化ワクチン |
| EP0294071A3 (en) * | 1987-06-03 | 1990-08-01 | Merck & Co. Inc. | Hepatitis b vaccines made with pre-formed aluminum hydroxide gels, and processes thereof |
| EP0835663B1 (en) * | 1992-05-23 | 2009-09-30 | GlaxoSmithKline Biologicals S.A. | Combined vaccines comprising Hepatitis B surface antigen and other antigens |
| AU4932493A (en) * | 1992-09-25 | 1994-04-26 | Dynagen, Inc. | An immunobooster for delayed release of immunogen |
| US6051238A (en) * | 1996-12-20 | 2000-04-18 | Merck & Co., Inc. | Stabilizers for lyophilized mumps vaccines |
| US6290967B1 (en) * | 1996-12-20 | 2001-09-18 | Merck & Co., Inc. | Stabilizers for lyophilized vaccines |
| KR20030020294A (ko) * | 2000-06-08 | 2003-03-08 | 파우더젝트 백신, 인코포레이티드 | 분말 조성물 |
| UA79735C2 (uk) | 2000-08-10 | 2007-07-25 | Глаксосмітклайн Байолоджікалз С.А. | Очищення антигенів вірусу гепатиту b (hbv) для використання у вакцинах |
| EP1399131A2 (en) | 2001-06-08 | 2004-03-24 | Powderject Vaccines, Inc. | Spray freeze-dried compositions |
| KR20030025480A (ko) * | 2001-09-21 | 2003-03-29 | 보령제약 주식회사 | 약독화 수두 생바이러스 백신용 무단백질 안정화제 |
| US20060228369A1 (en) * | 2005-04-11 | 2006-10-12 | Program For Appropriate Technology In Health | Stabilization and preservation of temperature-sensitive vaccines |
| KR20080059289A (ko) | 2005-10-04 | 2008-06-26 | 알크-아벨로 에이/에스 | 고체 백신 제형 |
| TWI417113B (zh) | 2006-11-07 | 2013-12-01 | Acambis Inc | 以凍乾法穩定疫苗 |
| TW201043267A (en) * | 2009-03-19 | 2010-12-16 | Intervet Int Bv | In situ constituting a vaccine for administration to a predetermined herd of animals |
| JP5960120B2 (ja) | 2010-03-31 | 2016-08-02 | スタビリテック リミテッド | ウイルス粒子の安定化 |
| GB2499480A (en) * | 2010-03-31 | 2013-08-21 | Stabilitech Ltd | Method for preserving alum adjuvants and alum-adjuvanted vaccines |
| EP2552478B1 (en) | 2010-03-31 | 2016-12-21 | Stabilitech Ltd. | Excipients for stabilising viral particles |
| EP2723371B1 (en) | 2011-06-24 | 2019-10-23 | Merck Sharp & Dohme Corp. | Hpv vaccine formulations comprising aluminum adjuvant and methods of producing same |
| WO2013012022A1 (ja) | 2011-07-19 | 2013-01-24 | 中外製薬株式会社 | アルギニンアミドまたはその類似化合物を含む安定なタンパク質含有製剤 |
| GB201117233D0 (en) | 2011-10-05 | 2011-11-16 | Stabilitech Ltd | Stabilisation of polypeptides |
| JP5931449B2 (ja) * | 2012-01-11 | 2016-06-08 | 日東電工株式会社 | 医薬組成物及びその製造方法 |
| GB201406569D0 (en) | 2014-04-11 | 2014-05-28 | Stabilitech Ltd | Vaccine compositions |
| WO2017179614A1 (ja) * | 2016-04-15 | 2017-10-19 | 富士フイルム株式会社 | マイクロニードルアレイ |
| GB2562241B (en) | 2017-05-08 | 2022-04-06 | Stabilitech Biopharma Ltd | Vaccine compositions |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US2879202A (en) * | 1954-11-05 | 1959-03-24 | American Cyanamid Co | Stabilization of live viral vaccines by hexahydric alcohols |
| DE1617457A1 (de) * | 1966-12-16 | 1972-04-20 | Erba Carlo Spa | Verfahren zur Stabilisierung von Zubereitungen interferierender Virusprodukte |
| DE1617350C3 (de) * | 1967-06-22 | 1979-09-06 | Behringwerke Ag, 3550 Marburg | Verfahren zur Inaktivierung von biologischem Material |
| US3636191A (en) * | 1969-10-08 | 1972-01-18 | Cancer Res Inst | Vaccine against viral hepatitis and process |
| JPS5523253B2 (ko) * | 1973-12-28 | 1980-06-21 |
-
1983
- 1983-07-05 JP JP58122945A patent/JPS6013718A/ja active Granted
-
1984
- 1984-06-28 AU AU29993/84A patent/AU572162B2/en not_active Ceased
- 1984-07-02 KR KR1019840003814A patent/KR910005888B1/ko not_active IP Right Cessation
- 1984-07-04 AT AT84107773T patent/ATE41309T1/de not_active IP Right Cessation
- 1984-07-04 EP EP84107773A patent/EP0130619B1/en not_active Expired
- 1984-07-04 DE DE8484107773T patent/DE3477139D1/de not_active Expired
- 1984-07-05 CA CA000458226A patent/CA1237076A/en not_active Expired
Also Published As
| Publication number | Publication date |
|---|---|
| AU572162B2 (en) | 1988-05-05 |
| JPS6013718A (ja) | 1985-01-24 |
| DE3477139D1 (en) | 1989-04-20 |
| EP0130619A3 (en) | 1985-04-10 |
| EP0130619B1 (en) | 1989-03-15 |
| CA1237076A (en) | 1988-05-24 |
| AU2999384A (en) | 1985-01-10 |
| JPH0437806B2 (ko) | 1992-06-22 |
| KR910005888B1 (ko) | 1991-08-06 |
| EP0130619A2 (en) | 1985-01-09 |
| ATE41309T1 (de) | 1989-04-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| KR850002277A (ko) | 동결건조 b형 간염 왁진조성물 및 그 제조방법 | |
| KR850006450A (ko) | 동결건조된 b형간염 백신의 제조방법 | |
| KR860003019A (ko) | 안정한 에리트로포에틴 제제의 제조방법 | |
| Gordon Jr et al. | Role of serum albumin in lipemia clearing reaction | |
| SE7907316L (sv) | Aminosyralosning | |
| SE8201350L (sv) | Sett att framstella frystorkade liposomblandningar | |
| KR850005455A (ko) | r-인터페론 안정화 조성물의 제조방법 | |
| KR930007453A (ko) | 동결건조 이포스파미드 조성물 | |
| KR950703987A (ko) | G-csf의 안정한 동결건조된 약제학적 제제(stable lyophilized pharma ceutical preparations g-csf) | |
| JP2001518447A (ja) | 生ウイルスワクチン用組換えヒト血清アルブミン含有安定剤 | |
| AR074958A2 (es) | Composicion farmaceutica liofilizada de anticuerpos monoclonales o policlonales y procedimiento para su produccion | |
| BE1001533A3 (fr) | Vaccin vivant attenue stabilise et sa fabrication. | |
| IE38825B1 (en) | Stable viral preparations | |
| JPS54147916A (en) | Preparation of urokinase injection | |
| US11878054B2 (en) | VLP stabilized vaccine compositions | |
| KR850001700A (ko) | 단순 헤르페스 바이러스 서브유니트 왁진(Herpes Simplex Virus Subuait Vaccine)의 제조방법 | |
| AR034226A2 (es) | Procedimiento perfeccionado para estabilizar proteinas. | |
| KR900015749A (ko) | 인터루킨-1제형 | |
| KR840002657A (ko) | 인터페론 조성물의 제조방법 | |
| SE9003844L (sv) | Naeringstillsats | |
| TH3859A (ko) | ||
| TH2141A (ko) | ||
| KR860008199A (ko) | 우로키나제 전구체의 안정화방법 | |
| GB1189935A (en) | Dried Stable Anti-Tumour Preparations and a process for preparing the same | |
| KR890011894A (ko) | 세팔로스포린 유도체를 안정화제로 건조시켜 안정화하는 방법 및 세팔로스포린 유도체를 함유하는 안정한 조성물 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A201 | Request for examination | ||
| E902 | Notification of reason for refusal | ||
| G160 | Decision to publish patent application | ||
| E701 | Decision to grant or registration of patent right | ||
| GRNT | Written decision to grant | ||
| FPAY | Annual fee payment |
Payment date: 20030627 Year of fee payment: 13 |
|
| EXPY | Expiration of term |